Chemoprevention of head and neck cancer with celecoxib and erlotinib: Results of a phase Ib and pharmacokinetic study

Cancer Prevention Research

Volumn 7, Issue 3, 2014, Pages 283-291

  Saba, Nabil F ^a   Hurwitz, Selwyn J ^b   Kono, Scott A ^a   Yang, Chung S ^e   Zhao, Yang ^e   Chen, Zhengjia ^c   Sica, Gabe ^a   Mul̈ler, Susan ^a   Moreno Williams, Rachel ^a   Lewis, Melinda ^a   Grist, William ^a   Chen, Amy Y ^a   Moore, Charles E ^a   Owonikoko, Taofeek K ^a   Ramalingam, Suresh ^a   Beitler, Jonathan J ^a   Nannapaneni, Sreenivas ^a   Shin, Hyung Ju C ^d   Grandis, Jennifer R ^f   Khuri, Fadlo R ^a   Chen, Zhuo Georgia ^a   Shin, Dong M ^a   more..

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e RUTGERS UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CELECOXIB; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL CRAMP; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DRY SKIN; DYSPLASIA; DYSPNEA; ERYTHROLEUKOPLAKIA; ERYTHROPLASIA; FATIGUE; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPROTEINEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LEUKOPLAKIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOUTH MUCOSA; MOUTH SQUAMOUS CELL CARCINOMA; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; ORAL BIOPSY; PHASE 1 CLINICAL TRIAL; PRECANCER AND CANCER-IN-SITU; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PRURITUS; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; STREPTOCOCCAL PHARYNGITIS; TREATMENT DURATION; TREATMENT RESPONSE; UROSEPSIS; VERY ELDERLY; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE COURSE; HEAD AND NECK NEOPLASMS; METABOLISM; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOPREVENTION; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; QUINAZOLINES; SULFONAMIDES;

EID: 84895503989     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0215     Document Type: Article

References (40)

1. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515-22. (Pubitemid 27211827)
2. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
3. Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res 1988;48:6753-7. (Pubitemid 19012200)
4. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:3153-9. (Pubitemid 24208920)
5. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-92. (Pubitemid 26303896)
6. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-54.
7. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000;59:753-67. (Pubitemid 30232318)
8. Saba NF, Khuri FR, Shin DM. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology (Williston Park) 2006;20:153-61. (Pubitemid 46931063)
9. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-22. (Pubitemid 41820645)
10. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6. (Pubitemid 38050040)
11. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-66. (Pubitemid 46206877)
12. Cohen EG, Almahmeed T, Du B, Golijanin D, Boyle JO, Soslow RA, et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res 2003;9:3425-30. (Pubitemid 37082739)
13. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-4. (Pubitemid 29135955)
14. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:5930-9. (Pubitemid 39180975)
15. Saba NF, Choi M, Muller S, Shin HJ, Tighiouart M, Papadimitrakopoulou VA, et al. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res 2009;2:823-9.
16. Papadimitrakopoulou VA, William WN Jr., Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14:2095-101. (Pubitemid 351551121)
17. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 2005;69 Suppl 1:28-32. (Pubitemid 41433539)
18. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000;60:6045- 51.
19. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946- 52.
20. Nathan CO, Leskov IL, Lin M, Abreo FW, Shi R, Hartman GH, et al. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer. 2001;92:1888-95. (Pubitemid 32952508)
21. Ondrey FG, Juhn SK, Adams GL. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996;106:129-34. (Pubitemid 26054361)
22. Scioscia KA, Snyderman CH, Rueger R, Reddy J, D'Amico F, Comsa S, et al. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinfl ammatory drugs. Am J Otolaryngol 1997;18:1-8. (Pubitemid 27036557)
23. Panje WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981;107:658-63. (Pubitemid 11027717)
24. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, et al. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res 2008;1:339-48.
25. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11:6261-9. (Pubitemid 41262957)
26. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4:1448-55.
27. Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013;19:1244-56.
28. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983;11:303- 19.
29. White-Koning M, Civade E, Geoerger B, Thomas F, Le Deley MC, Hennebelle I, et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res 2011;17:4862-71.
30. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006;80:136-45. (Pubitemid 44160689)
31. Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/ pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 2009;45:2316-23.
32. Beal S SL, Bookman A, Bauer RJ. NONMEM user's guides. 1989-2009. Ellicott City, MD: ICON Development Solutions; 2009.
33. Kao J, Genden EM, Chen CT, Rivera M, Tong CC, Misiukiewicz K, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011;117:3173-81.
34. Dogne JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des 2006;12:971-5.
35. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002;24:792-9. (Pubitemid 34857307)
36. Amin AR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009;27:2712-25.
37. Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res 2010;3:900-9.
38. Amin AR, Wang D, Zhang H, Peng S, Shin HJ, Brandes JC, et al. Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem 2010;285:34557-65.
39. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007;24:2187-97. (Pubitemid 350060706)
40. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011;13:143-51.